ThermoGenesis (THMO) 10-Q 19 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		2,843,601
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,800,000	$ 2,400,000
Accounts receivable, net of allowance for doubtful accounts of $278,000 ($419,000 at December 31, 2018)	4,470,000	1,509,000
Inventories, net of reserves of $399,000 ($258,000 at December 31, 2018)	3,405,000	4,493,000
Prepaid expenses and other current assets	451,000	224,000
Total current assets	11,126,000	8,626,000
Restricted cash – long term	1,000,000	1,000,000
Equipment and leasehold improvements, net	2,251,000	2,562,000
Right-of-use operating lease assets, net	887,000
Goodwill	781,000	781,000
Intangible assets, net	1,498,000	1,591,000
Other assets	48,000	51,000
Total assets	17,591,000	14,611,000
Current liabilities:
Accounts payable	1,874,000	2,423,000
Accrued payroll and related expenses	404,000	703,000
Deferred revenue – short term	840,000	485,000
Interest payable – related party	1,398,000	1,513,000
Other current liabilities	1,175,000	1,241,000
Total current liabilities	5,691,000	6,365,000
Convertible promissory note – related party, less debt discount of $5,781,000 ($6,026,000 at December 31, 2018)	2,932,000	1,174,000
Convertible promissory note, plus debt premium of $80,000 ($0 at December 31, 2018)	665,000
Note payable	1,000,000
Operating lease obligations – long term	794,000
Deferred revenue – long term	1,855,000	303,000
Other noncurrent liabilities	23,000	38,000
Total liabilities	12,960,000	7,880,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized; none issued and outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 2,704,837 issued and outstanding (2,168,337 at December 31, 2018)	3,000	2,000
Additional paid in capital	236,830,000	235,888,000
Accumulated deficit	(232,885,000)	(227,435,000)
Accumulated other comprehensive loss	(4,000)	(13,000)
Total ThermoGenesis Holdings, Inc. stockholders’ equity	3,944,000	8,442,000
Noncontrolling interest	687,000	(1,711,000)
Total stockholders’ equity	4,631,000	6,731,000
Total liabilities and stockholders’ equity	$ 17,591,000	$ 14,611,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 278,000	$ 419,000
Inventories, reserves	399,000	258,000
Debt discount
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	2,704,837	2,168,337
Common stock, shares outstanding (in shares)	2,704,837	2,168,337
Convertible Promissory Note [Member]
Debt discount	$ 5,781,000	$ 6,026,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net revenues	$ 4,058,000	$ 3,113,000	$ 11,325,000	$ 6,984,000
Cost of revenues	2,163,000	2,458,000	6,220,000	5,614,000
Gross profit	1,895,000	655,000	5,105,000	1,370,000
Expenses:
Sales and marketing	502,000	364,000	1,227,000	1,048,000
Research and development	584,000	611,000	1,758,000	2,560,000
General and administrative	1,139,000	1,615,000	3,617,000	6,256,000
Impairment charges				27,202,000
Total operating expenses	2,225,000	2,590,000	6,602,000	37,066,000
Loss from operations	(330,000)	(1,935,000)	(1,497,000)	(35,696,000)
Fair value change of derivative instruments	(2,000)	24,000	(2,000)	591,000
Interest expense	(1,188,000)	(835,000)	(3,531,000)	(1,928,000)
Loss on extinguishment of debt	(840,000)		(840,000)
Other expense	(13,000)	(18,000)	(25,000)	(63,000)
Total other expense	(2,043,000)	(829,000)	(4,398,000)	(1,400,000)
Loss before benefit for income taxes	(2,373,000)	(2,764,000)	(5,895,000)	(37,096,000)
Benefit for income taxes				3,451,000
Net loss	(2,373,000)	(2,764,000)	(5,895,000)	(33,645,000)
Loss attributable to noncontrolling interests	(91,000)	(175,000)	(445,000)	(1,088,000)
Net loss attributable to common stockholders	(2,282,000)	(2,589,000)	(5,450,000)	(32,557,000)
Net loss	(2,373,000)	(2,764,000)	(5,895,000)	(33,645,000)
Other comprehensive loss:
Foreign currency translation adjustments	16,000	23,000	9,000	51,000
Comprehensive loss	(2,357,000)	(2,741,000)	(5,886,000)	(33,594,000)
Comprehensive loss attributable to noncontrolling interests	(91,000)	(175,000)	(445,000)	(1,088,000)
Comprehensive loss attributable to common stockholders	$ (2,266,000)	$ (2,566,000)	$ (5,441,000)	$ (32,506,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.78)	$ (1.17)	$ (2)	$ (19.90)
Weighted average common shares outstanding basic and diluted (in shares)	2,913,198	2,214,600	2,720,502	1,636,299

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	[1]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017	1,090,664
Balance at Dec. 31, 2017	$ 1,000	$ 221,381,000	$ (187,640,000)	$ (43,000)		$ (487,000)	$ 33,212,000
Stock-based compensation		137,000					137,000
Foreign currency translation				7,000			7,000
Net loss			(2,960,000)			(410,000)	(3,370,000)
Issuance of pre-funded warrants in financing, net of offering costs		1,213,000					1,213,000
Issuance of common stock and pre-funded warrants, net of offering costs (in shares)	60,697
Cumulative-effect adjustment from adoption of ASC 606			(79,000)				(79,000)
Balance (in shares) at Mar. 31, 2018	1,151,361
Balance at Mar. 31, 2018	$ 1,000	222,731,000	(190,679,000)	(36,000)		(897,000)	31,120,000
Balance (in shares) at Dec. 31, 2017	1,090,664
Balance at Dec. 31, 2017	$ 1,000	221,381,000	(187,640,000)	(43,000)		(487,000)	33,212,000
Foreign currency translation							51,000
Balance (in shares) at Sep. 30, 2018	2,168,067
Balance at Sep. 30, 2018	$ 2,000	235,711,000	(220,276,000)	8,000		(1,575,000)	13,870,000
Balance (in shares) at Mar. 31, 2018	1,151,361
Balance at Mar. 31, 2018	$ 1,000	222,731,000	(190,679,000)	(36,000)		(897,000)	31,120,000
Stock-based compensation		163,000					163,000
Exercise of pre-funded warrants (in shares)	269,167
Exercise of pre-funded warrants		27,000					27,000
Discount due to beneficial conversion features		7,200,000					7,200,000
Foreign currency translation				21,000			21,000
Net loss			(27,008,000)			(503,000)	(27,511,000)
Issuance of pre-funded warrants in financing, net of offering costs	$ 1,000	4,791,000					4,792,000
Issuance of common stock and pre-funded warrants, net of offering costs (in shares)	647,497
Stock-based compensation (in shares)	42
Balance (in shares) at Jun. 30, 2018	2,068,067
Balance at Jun. 30, 2018	$ 2,000	234,912,000	(217,687,000)	(15,000)		(1,400,000)	15,812,000
Stock-based compensation		175,000					175,000
Foreign currency translation				23,000			23,000
Net loss			(2,589,000)			(175,000)	(2,764,000)
Issuance of pre-funded warrants in financing, net of offering costs		624,000					624,000
Issuance of common stock and pre-funded warrants, net of offering costs (in shares)	100,000
Cumulative-effect adjustment from adoption of ASC 606
Balance (in shares) at Sep. 30, 2018	2,168,067
Balance at Sep. 30, 2018	$ 2,000	235,711,000	(220,276,000)	8,000		(1,575,000)	13,870,000
Balance (in shares) at Dec. 31, 2018	2,168,337
Balance at Dec. 31, 2018	$ 2,000	235,888,000	(227,435,000)	(13,000)		(1,711,000)	6,731,000
Stock-based compensation		81,000					81,000
Exercise of pre-funded warrants (in shares)	50,000
Exercise of pre-funded warrants		5,000					5,000
Discount due to beneficial conversion features		1,513,000					1,513,000
Reorganization of subsidiary and related change in non-controlling interest		(2,843,000)				2,843,000
Foreign currency translation				(4,000)			(4,000)
Net loss			(1,871,000)			(176,000)	(2,047,000)
Balance (in shares) at Mar. 31, 2019	2,218,337
Balance at Mar. 31, 2019	$ 2,000	234,644,000	(229,306,000)	(17,000)		956,000	6,279,000
Balance (in shares) at Dec. 31, 2018	2,168,337
Balance at Dec. 31, 2018	$ 2,000	235,888,000	(227,435,000)	(13,000)		(1,711,000)	6,731,000
Reorganization of subsidiary and related change in non-controlling interest						2,843,000
Foreign currency translation							9,000
Balance (in shares) at Sep. 30, 2019	2,704,837
Balance at Sep. 30, 2019	$ 3,000	236,830,000	(232,885,000)	(4,000)		687,000	4,631,000
Balance (in shares) at Mar. 31, 2019	2,218,337
Balance at Mar. 31, 2019	$ 2,000	234,644,000	(229,306,000)	(17,000)		956,000	6,279,000
Stock-based compensation		125,000					125,000
Exercise of pre-funded warrants (in shares)	150,000
Exercise of pre-funded warrants		18,000					18,000
Discount due to beneficial conversion features		800,000					800,000
Foreign currency translation				(3,000)			(3,000)
Net loss			(1,297,000)			(178,000)	(1,475,000)
Issuance of pre-funded warrants in financing, net of offering costs		756,000					756,000
Balance (in shares) at Jun. 30, 2019	2,368,337
Balance at Jun. 30, 2019	$ 2,000	236,343,000	(230,603,000)	(20,000)		778,000	6,500,000
Stock-based compensation		253,000					253,000
Exercise of pre-funded warrants (in shares)	216,500
Exercise of pre-funded warrants	$ 1,000	18,000					19,000
Foreign currency translation				16,000			16,000
Net loss			(2,282,000)			(91,000)	(2,373,000)
Conversion of note payable to stock (in shares)	120,000
Conversion of note payable to stock		216,000					216,000
Balance (in shares) at Sep. 30, 2019	2,704,837
Balance at Sep. 30, 2019	$ 3,000	$ 236,830,000	$ (232,885,000)	$ (4,000)		$ 687,000	$ 4,631,000
[1]	Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (5,895,000)	$ (33,645,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	604,000	506,000
Stock based compensation expense	459,000	475,000
Amortization of debt discount	1,799,000	800,000
(Recovery of)/reserve for excess and slow-moving inventories	141,000	(126,000)
(Recovery of)/reserve for bad debt expense	(53,000)	75,000
Change in fair value of derivative obligation	2,000	(591,000)
Deferred income tax benefit		(3,451,000)
Loss on disposal of equipment	20,000	451,000
Loss on extinguishment of debt	840,000
Impairment of intangible asset		27,202,000
Net change in operating assets and liabilities:
Accounts receivable	(2,908,000)	543,000
Inventories	980,000	336,000
Prepaid expenses and other assets	(227,000)	304,000
Accounts payable	(542,000)	(407,000)
Related party payable	(116,000)	(135,000)
Accrued payroll and related expenses	(298,000)	(147,000)
Deferred revenue	354,000	66,000
Other current liabilities	(145,000)	314,000
Long term deferred revenue and other noncurrent liabilities	1,467,000	(1,000)
Net cash used in operating activities	(3,518,000)	(7,431,000)
Cash flows from investing activities:
Capital expenditures	(178,000)	(985,000)
Net cash used in investing activities	(178,000)	(985,000)
Cash flows from financing activities:
Payments on finance lease obligations	(15,000)	(28,000)
Proceeds from long-term debt	1,800,000
Proceeds from convertible promissory note – related party	1,513,000	500,000
Proceeds from exercise of pre-funded warrants	42,000
Proceeds from issuance of common stock and pre-funded warrants	756,000	6,655,000
Net cash provided by financing activities	4,096,000	7,127,000
Effects of exchange rate changes on cash and cash equivalents		(4,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	400,000	(1,293,000)
Cash, cash equivalents and restricted cash at beginning of period	3,400,000	3,513,000
Cash, cash equivalents and restricted cash at end of period	3,800,000	2,220,000
Supplemental disclosures of cash flow information:
Cash paid for interest	1,613,000	664,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	2,313,000	7,200,000
Right-to-use asset acquired under operating lease	966,000
Conversion of debt to common stock	216,000
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note	1,473,000
Transfer of equipment to inventories	33,000	172,000
Transfer of inventories to equipment		$ 420,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Basis of Presentation and Summary of Significant Accounting Policies Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” or the “Company”), formerly known as Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 ThermoGenesis Corp. (ThermoGenesis Corp), the Company’s fully owned device subsidiary, provides the AutoXpress ® ® ® For Clinical Bio-Banking Applications: • AXP ® • BioArchive ® For Point-of-Care Applications: • PXP ® For Large Scale Cell Processing and Biomanufacturing : • X X ® X ® X ® X ™ • CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (CMC) needs for manufacturing chimeric antigen receptor (CAR) T cell therapies. On January 1, 2019, July 2017 20% third 20% 80% 100% The Company reacquired the non-controlling interest shares in ThermoGenesis Corp. with a deficit of $1,711,000 20% $1,100,000. $2,843,000 ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics. Recent Corporate Name Change On November 1, 2019, Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not All historical share amounts disclosed herein have been retroactively restated to reflect the reverse split and subsequent share exchange. No Liquidity and Going Concern The Company has a Revolving Credit Agreement (Credit Agreement) with Boyalife Asset Holding II, Inc. (Refer to Note 3 September 30, 2019, $8,713,000 $10,000,000 may may no At September 30, 2019, $2,800,000 $5,435,000, $2,400,000 $2,261,000 December 31, 2018. one may The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The condensed consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. three nine September 30, 2019 not may December 31, 2019. 10 December 31, 2018.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Recently Adopted Accounting Standards In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 January 1, 2019. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000 no Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues of the Company’s reportable segments and product lines: Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 212,000 -- -- 212,000 CAR-TXpress 875,000 6,000 33,000 914,000 Other -- -- 19,000 19,000 Total Device Segment 3,585,000 408,000 52,000 4,045,000 Clinical Development Segment: Manual Disposables 9,000 -- -- 9,000 Other -- 4,000 -- 4,000 Total Clinical Development 9,000 4,000 -- 13,000 Total 3,594,000 412,000 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 711,000 -- -- 711,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other -- -- 40,000 40,000 Total Device Segment 9,900,000 1,283,000 73,000 11,256,000 Clinical Development Segment: Manual Disposables 53,000 -- -- 53,000 Other 5,000 11,000 -- 16,000 Total Clinical Development 58,000 11,000 -- 69,000 Total 9,958,000 1,294,000 73,000 11,325,000 Three Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,396,000 $ 70,000 $ -- $ 1,466,000 BioArchive 485,000 314,000 -- 799,000 Manual Disposables 254,000 -- -- 254,000 CAR-TXpress 517,000 -- -- 517,000 Other -- -- 23,000 23,000 Total Device Segment 2,652,000 384,000 23,000 3,059,000 Clinical Development Segment: Manual Disposables 8,000 -- -- 8,000 Bone Marrow -- 40,000 -- 40,000 Other -- 6,000 -- 6,000 Total Clinical Development 8,000 46,000 -- 54,000 Total $ 2,660,000 $ 430,000 $ 23,000 $ 3,113,000 Nine Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,930,000 $ 201,000 $ -- $ 3,131,000 BioArchive 1,357,000 969,000 -- 2,326,000 Manual Disposables 716,000 -- -- 716,000 CAR-TXpress 547,000 -- -- 547,000 Other 46,000 -- 56,000 102,000 Total Device Segment 5,596,000 1,170,000 56,000 6,822,000 Clinical Development Segment: Manual Disposables 31,000 -- -- 31,000 Bone Marrow -- 101,000 -- 101,000 Other -- 30,000 -- 30,000 Total Clinical Development 31,000 131,000 -- 162,000 Total $ 5,627,000 $ 1,301,000 $ 56,000 $ 6,984,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2019 $50,000 $480,000, $485,000 December 31, 2018 $840,000 September 30, 2019. Supply Agreement On August 30, 2019, X five two X first $2,000,000 January 1, 2021, The agreement contains covenants by the Company to negotiate in good faith regarding price reductions for the Products and, commencing in 2020, first Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3 Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis Corp. subsidiary. ● The Clinical Development Segment, utilizes autologous stem cell-based therapeutics in the vascular and orthopedic markets through the Company’s TotipotentRX subsidiary in Gurgaon, India. Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants (as described in Footnote 8 no 324,444 September 30, 2019 September 30: 2019 2018 Common stock equivalents of convertible promissory notes and accrued interest 6,013,667 4,626,667 Vested Series A warrants 40,442 40,442 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,300,091 1,319,728 Stock options 296,029 118,830 Total 7,720,082 6,175,520 ______________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3. Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( $8,713,000 $7,200,000 September 30, 2019 December 31, 2018, $1,287,000 may may no The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option contained a beneficial conversion feature and as a result of the modifications to the conversion price, the Company recorded a debt discount in the amount of $7,200,000 $1,513,000 March 31, 2019. $586,000 $1,758,000 three nine September 30, 2019, $450,000 $800,000 three nine September 30, 2018. $471,000 $1,398,000 three nine September 30, 2019, $385,000 $1,128,000 three nine September 30, 2018. September 30, 2019, $1,398,000 $1,513,000 December 31, 2018 Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two During the three nine September 30, 2019, $214,000 $794,000, $267,000 $536,000 three nine September 30, 2018 License Agreement On March 12, 2018, X ® Pursuant to the terms of the Agreement, ThermoGenesis granted IncoCell an exclusive license to purchase and use, at a discounted purchase price, X ten may ninety 90 $82,000 three nine September 30, 2019, $7,000 three nine September 30, 2018. no three nine September 30, 2019 2018.

Note 4 - Convertible Promissory

Note 4 - Convertible Promissory Note	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	4. Convertible Promissory Note On January 29, 2019, $800,000 “January 2019 six $1.80 2 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 January 2019 may On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. $60,000 $117,000 three nine September 30, 2019, The January 2019 January 2019 may January 2019 On July 23, 2019, No. 1 January 2019 January 2019 July 29, 2020 July 31, 2022. January 2019 January 2019 January 2019 10% January 2019 $840,000. $1,473,000 $556,000 $ 20,000 $57,000 January 2019 three nine September 30, 2019, Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 % ( 1 For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 90% $0.50 During the quarter ended September 30, 2019, $216,000 120,000 $30,000 September 30, 2019. On July 23, 2019, $1,000,000 “July 2019 six July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. July 2019 not second 2020 fourteen The July 2019 may six July 2019 may July 2019 July 2019

Note 5 - Leases

Note 5 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5. Leases The Company determines whether a contract contains a lease at inception. Our material operating lease consists of office space which has a remaining term of 4.7 Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of remaining minimum lease payments. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not The following summarizes the Company’s operating leases: September 30, 2019 Right-of-use operating lease assets, net $ 887,000 Current lease liability 110,000 Non-current lease liability 794,000 September 30, 2019 Weighted average remaining lease term 4.7 Discount rate 22% Maturities of lease liabilities by calendar year for our operating leases are as follows: Period of October 1, 2019 through December 31, 2019 $ 74,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 2024 138,000 Total lease payments $ 1,471,000 Less: imputed interest (567,000 ) Present value of operating lease liabilities $ 904,000 Statement of Cash Flows In January 2019, $966,000 $74,000 $217,000 three nine September 30, 2019 Operating Lease Costs Operating lease costs were $103,000 $309,000 three nine September 30, 2019. 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities in the accompanying condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively in the accompanying statements of operations. These leases are not September 30, 2019.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6. Commitments and Contingencies Financial Covenants Effective May 15, 2017, one not $2,000,000. September 30, 2019. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine September 30, 2019 Balance at December 31, 2018 $ 186,000 Warranties issued during the period 242,000 Settlements made during the period (141,000 ) Changes in liability for pre-existing warranties during the period (39,000 ) Balance at September 30, 2019 $ 248,000 Contingencies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 $300,000 June 30, 2019) August 2016. October 2017, $1,000,000 June 26, 2018. September 24, 2018, July 22, 2019, August 6, 2019, November 18, 2019. November 13, 2019 No No September 30, 2019. In the normal course of operations, the Company may September 30, 2019, may not

Note 7 - Derivative Obligations

Note 7 - Derivative Obligations	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7. Derivative Obligations Series A Warrants Series A warrants to purchase 40,442 June 30, 2016. Series A September 30, 2019 December 31, 2018 Market price of common stock $6.63 $2.70 Expected volatility 93% 94% Contractual term (years) 1.4 2.2 Discount rate 1.70% 2.48% Dividend rate 0% 0% Exercise price $80.00 $80.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a loss of $2,000 three nine September 30, 2019, $24,000 $591,000 three nine September 30, 2018, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2019 December 31, 2018, Derivative Obligation September 30, 2019 December 31, 2018 Balance $ 3,000 $ 1,000 Level 1 $ -- $ -- Level 2 $ -- $ -- Level 3 $ 3,000 $ 1,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the nine September 30, 2019: Amount Balance – December 31, 2018 $ 1,000 Change in fair value of derivative obligation 2,000 Balance – September 30, 2019 $ 3,000

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	8. Stockholders’ Equity On April 18, 2019, “April 444,445 $1.70 $756,000. April April 26, 2019 Each pre-funded warrant is immediately exercisable for one $0.10 not 4.99% 9.99%, may not 61st may not 9.99%. Subject to certain exceptions, in the event the Company sells or issues any shares of common stock or common stock equivalents at a lower price during the period beginning on the closing date of the April three sixty-five 365 Stock Based Compensation The Company recorded stock-based compensation of $253,000 $459,000 three nine September 30, 2019, $175,000 $475,000 three nine September 30, 2018, Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Cost of revenues $ 1,000 $ 3,000 $ 2,000 $ 9,000 Sales and marketing 110,000 11,000 166,000 29,000 Research and development 38,000 30,000 75,000 86,000 General and administrative 104,000 131,000 216,000 351,000 $ 253,000 $ 175,000 $ 459,000 $ 475,000 The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2018 302,368 $ 13.99 Granted 10,200 $ 4.38 Forfeited (16,539 ) $ 11.50 Outstanding at September 30, 2019 296,029 $ 13.80 8.6 $ 763,499 Vested and expected to vest at September 30, 2019 215,932 $ 15.95 8.4 $ 525,700 Exercisable at September 30, 2019 94,978 $ 25.70 7.6 $ 171,726 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no nine September 30, 2019. Warrants A summary of warrant activity for the nine September 30, 2019 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2018 1,726,523 $ 29.88 Warrants granted (1) 444,445 $ 0.10 Warrants expired (19,637 ) $ 417.00 Warrants exercised (416,500 ) $ 0.10 Outstanding at September 30, 2019 1,734,831 $ 25.02 Exercisable at September 30, 2019 1,664,978 $ 22.72 _______________________ ( 1 See Footnote 1

Note 9 - Segment Reporting

Note 9 - Segment Reporting	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	9. Segment Reporting The Company has two The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The Clinical Development Segment utilizes autologous stem cell-based therapeutics in the vascular and orthopedic markets. The following table summarizes the operating results of the Company’s reportable segments: Three Months Ended September 30, 2019 Device Clinical Development Total Net revenues $ 4,045,000 $ 13,000 $ 4,058,000 Cost of revenues 2,126,000 37,000 2,163,000 Gross profit 1,919,000 (24,000 ) 1,895,000 Operating expenses 1,871,000 354,000 2,225,000 Operating income / (loss) $ 48,000 $ (378,000 ) $ (330,000 ) Depreciation and amortization $ 149,000 $ 53,000 $ 202,000 Stock-based compensation expense $ 201,000 $ 52,000 $ 253,000 Three Months Ended September 30, 2018 Device Clinical Development Total Net revenues $ 3,059,000 $ 54,000 $ 3,113,000 Cost of revenues 2,383,000 75,000 2,458,000 Gross profit 676,000 (21,000 ) 655,000 Operating expenses 1,969,000 621,000 2,590,000 Operating loss $ (1,293,000 ) $ (642,000 ) $ (1,935,000 ) Depreciation and amortization $ 100,000 $ 74,000 $ 174,000 Stock-based compensation expense $ 8,000 $ 167,000 $ 175,000 Nine Months Ended September 30, 2019 Device Clinical Development Total Net revenues $ 11,256,000 $ 69,000 $ 11,325,000 Cost of revenues 6,082,000 138,000 6,220,000 Gross profit 5,174,000 (69,000 ) 5,105,000 Operating expenses 5,295,000 1,307,000 6,602,000 Operating loss $ (121,000 ) $ (1,376,000 ) $ (1,497,000 ) Depreciation and amortization $ 381,000 $ 223,000 $ 604,000 Stock-based compensation expense $ 294,000 $ 165,000 $ 459,000 Goodwill $ 781,000 $ -- $ 781,000 Total assets $ 15,620,000 $ 1,971,000 $ 17,591,000 Nine Months Ended September 30, 2018 Device Clinical Development Total Net revenues $ 6,822,000 $ 162,000 $ 6,984,000 Cost of revenues 5,419,000 195,000 5,614,000 Gross profit 1,403,000 (33,000 ) 1,370,000 Operating expenses 6,858,000 30,208,000 37,066,000 Operating loss $ (5,455,000 ) $ (30,241,000 ) $ (35,696,000 ) Depreciation and amortization $ 296,000 $ 210,000 $ 506,000 Impairment Charges $ -- $ 27,202,000 $ 27,202,000 Stock-based compensation expense $ 88,000 $ 387,000 $ 475,000 Total assets $ 10,213,000 $ 11,386,000 $ 21,599,000

Note 10 - Major Customers and A

Note 10 - Major Customers and Accounts Receivable	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10. Major Customers and Accounts Receivable The Company had certain customers whose revenue individually represented 10% 10% For the three September 30, 2019 2018, one 27% 15% second 13% 15% nine September 30, 2019 2018, one 29% 19% 13% 7% At September 30, 2019, three 72% December 31, 2018 four 77%

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	11. Subsequent Events On October 30, 2019, November 1, 2019. October 30, 2019, 12:01 November 1, 2019. On October 21, 2019, December 31, 2019. 20% 115% $1.0 fourth

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” or the “Company”), formerly known as Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 ThermoGenesis Corp. (ThermoGenesis Corp), the Company’s fully owned device subsidiary, provides the AutoXpress ® ® ® For Clinical Bio-Banking Applications: • AXP ® • BioArchive ® For Point-of-Care Applications: • PXP ® For Large Scale Cell Processing and Biomanufacturing : • X X ® X ® X ® X ™ • CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (CMC) needs for manufacturing chimeric antigen receptor (CAR) T cell therapies. On January 1, 2019, July 2017 20% third 20% 80% 100% The Company reacquired the non-controlling interest shares in ThermoGenesis Corp. with a deficit of $1,711,000 20% $1,100,000. $2,843,000 ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics.
Reverse Stock Split [Policy Text Block]	Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not All historical share amounts disclosed herein have been retroactively restated to reflect the reverse split and subsequent share exchange. No
Substantial Doubt about Going Concern [Policy Text Block]	Liquidity and Going Concern The Company has a Revolving Credit Agreement (Credit Agreement) with Boyalife Asset Holding II, Inc. (Refer to Note 3 September 30, 2019, $8,713,000 $10,000,000 may may no At September 30, 2019, $2,800,000 $5,435,000, $2,400,000 $2,261,000 December 31, 2018. one may The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation.
Interim Reporting [Policy Text Block]	Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. three nine September 30, 2019 not may December 31, 2019. 10 December 31, 2018.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In June 2018, 2018 07, “Compensation-Stock Compensation (Topic 718 718 January 1, 2019. not In February 2016, 2016 02 Leases January 1, 2019. The new standard requires lessees to recognize both the right-of-use assets and lease liabilities in the balance sheet for most leases, whereas under previous GAAP only finance lease liabilities (previously referred to as capital leases) were recognized in the balance sheet. In addition, the definition of a lease has been revised which may not The new standard provides a number of transition practical expedients, which the Company has elected, including: ● A “package of three” expedients that must be taken together and allow entities to ( 1 not 2 3 not ● An implementation expedient which allows the requirements of the standard in the period of adoption with no The impact of adoption did not January 1, 2019 one January 2019, five $966,000 no
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues of the Company’s reportable segments and product lines: Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 212,000 -- -- 212,000 CAR-TXpress 875,000 6,000 33,000 914,000 Other -- -- 19,000 19,000 Total Device Segment 3,585,000 408,000 52,000 4,045,000 Clinical Development Segment: Manual Disposables 9,000 -- -- 9,000 Other -- 4,000 -- 4,000 Total Clinical Development 9,000 4,000 -- 13,000 Total 3,594,000 412,000 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 711,000 -- -- 711,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other -- -- 40,000 40,000 Total Device Segment 9,900,000 1,283,000 73,000 11,256,000 Clinical Development Segment: Manual Disposables 53,000 -- -- 53,000 Other 5,000 11,000 -- 16,000 Total Clinical Development 58,000 11,000 -- 69,000 Total 9,958,000 1,294,000 73,000 11,325,000 Three Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,396,000 $ 70,000 $ -- $ 1,466,000 BioArchive 485,000 314,000 -- 799,000 Manual Disposables 254,000 -- -- 254,000 CAR-TXpress 517,000 -- -- 517,000 Other -- -- 23,000 23,000 Total Device Segment 2,652,000 384,000 23,000 3,059,000 Clinical Development Segment: Manual Disposables 8,000 -- -- 8,000 Bone Marrow -- 40,000 -- 40,000 Other -- 6,000 -- 6,000 Total Clinical Development 8,000 46,000 -- 54,000 Total $ 2,660,000 $ 430,000 $ 23,000 $ 3,113,000 Nine Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,930,000 $ 201,000 $ -- $ 3,131,000 BioArchive 1,357,000 969,000 -- 2,326,000 Manual Disposables 716,000 -- -- 716,000 CAR-TXpress 547,000 -- -- 547,000 Other 46,000 -- 56,000 102,000 Total Device Segment 5,596,000 1,170,000 56,000 6,822,000 Clinical Development Segment: Manual Disposables 31,000 -- -- 31,000 Bone Marrow -- 101,000 -- 101,000 Other -- 30,000 -- 30,000 Total Clinical Development 31,000 131,000 -- 162,000 Total $ 5,627,000 $ 1,301,000 $ 56,000 $ 6,984,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2019 $50,000 $480,000, $485,000 December 31, 2018 $840,000 September 30, 2019. Supply Agreement On August 30, 2019, X five two X first $2,000,000 January 1, 2021, The agreement contains covenants by the Company to negotiate in good faith regarding price reductions for the Products and, commencing in 2020, first
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 3
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (CODM), or decision-making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two ● The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis Corp. subsidiary. ● The Clinical Development Segment, utilizes autologous stem cell-based therapeutics in the vascular and orthopedic markets through the Company’s TotipotentRX subsidiary in Gurgaon, India.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants (as described in Footnote 8 no 324,444 September 30, 2019 September 30: 2019 2018 Common stock equivalents of convertible promissory notes and accrued interest 6,013,667 4,626,667 Vested Series A warrants 40,442 40,442 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,300,091 1,319,728 Stock options 296,029 118,830 Total 7,720,082 6,175,520 ______________ ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,255,000 $ 51,000 $ -- $ 2,306,000 BioArchive 243,000 351,000 -- 594,000 Manual Disposables 212,000 -- -- 212,000 CAR-TXpress 875,000 6,000 33,000 914,000 Other -- -- 19,000 19,000 Total Device Segment 3,585,000 408,000 52,000 4,045,000 Clinical Development Segment: Manual Disposables 9,000 -- -- 9,000 Other -- 4,000 -- 4,000 Total Clinical Development 9,000 4,000 -- 13,000 Total 3,594,000 412,000 52,000 $ 4,058,000 Nine Months Ended September 30, 2019 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 6,550,000 $ 160,000 $ -- $ 6,710,000 BioArchive 1,274,000 1,117,000 -- 2,391,000 Manual Disposables 711,000 -- -- 711,000 CAR-TXpress 1,365,000 6,000 33,000 1,404,000 Other -- -- 40,000 40,000 Total Device Segment 9,900,000 1,283,000 73,000 11,256,000 Clinical Development Segment: Manual Disposables 53,000 -- -- 53,000 Other 5,000 11,000 -- 16,000 Total Clinical Development 58,000 11,000 -- 69,000 Total 9,958,000 1,294,000 73,000 11,325,000 Three Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 1,396,000 $ 70,000 $ -- $ 1,466,000 BioArchive 485,000 314,000 -- 799,000 Manual Disposables 254,000 -- -- 254,000 CAR-TXpress 517,000 -- -- 517,000 Other -- -- 23,000 23,000 Total Device Segment 2,652,000 384,000 23,000 3,059,000 Clinical Development Segment: Manual Disposables 8,000 -- -- 8,000 Bone Marrow -- 40,000 -- 40,000 Other -- 6,000 -- 6,000 Total Clinical Development 8,000 46,000 -- 54,000 Total $ 2,660,000 $ 430,000 $ 23,000 $ 3,113,000 Nine Months Ended September 30, 2018 Device Revenue Service Revenue Other Revenue Total Revenue Device Segment: AXP $ 2,930,000 $ 201,000 $ -- $ 3,131,000 BioArchive 1,357,000 969,000 -- 2,326,000 Manual Disposables 716,000 -- -- 716,000 CAR-TXpress 547,000 -- -- 547,000 Other 46,000 -- 56,000 102,000 Total Device Segment 5,596,000 1,170,000 56,000 6,822,000 Clinical Development Segment: Manual Disposables 31,000 -- -- 31,000 Bone Marrow -- 101,000 -- 101,000 Other -- 30,000 -- 30,000 Total Clinical Development 31,000 131,000 -- 162,000 Total $ 5,627,000 $ 1,301,000 $ 56,000 $ 6,984,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2019 2018 Common stock equivalents of convertible promissory notes and accrued interest 6,013,667 4,626,667 Vested Series A warrants 40,442 40,442 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,300,091 1,319,728 Stock options 296,029 118,830 Total 7,720,082 6,175,520

Note 4 - Convertible Promisso_2

Note 4 - Convertible Promissory Note (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A September 30, 2019 December 31, 2018 Market price of common stock $6.63 $2.70 Expected volatility 93% 94% Contractual term (years) 1.4 2.2 Discount rate 1.70% 2.48% Dividend rate 0% 0% Exercise price $80.00 $80.00
Convertible Debt [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 %

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	September 30, 2019 Right-of-use operating lease assets, net $ 887,000 Current lease liability 110,000 Non-current lease liability 794,000 September 30, 2019 Weighted average remaining lease term 4.7 Discount rate 22%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Period of October 1, 2019 through December 31, 2019 $ 74,000 2020 301,000 2021 310,000 2022 319,000 2023 329,000 2024 138,000 Total lease payments $ 1,471,000 Less: imputed interest (567,000 ) Present value of operating lease liabilities $ 904,000

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2018 $ 186,000 Warranties issued during the period 242,000 Settlements made during the period (141,000 ) Changes in liability for pre-existing warranties during the period (39,000 ) Balance at September 30, 2019 $ 248,000

Note 7 - Derivative Obligatio_2

Note 7 - Derivative Obligations (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series A September 30, 2019 December 31, 2018 Market price of common stock $6.63 $2.70 Expected volatility 93% 94% Contractual term (years) 1.4 2.2 Discount rate 1.70% 2.48% Dividend rate 0% 0% Exercise price $80.00 $80.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Derivative Obligation September 30, 2019 December 31, 2018 Balance $ 3,000 $ 1,000 Level 1 $ -- $ -- Level 2 $ -- $ -- Level 3 $ 3,000 $ 1,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – December 31, 2018 $ 1,000 Change in fair value of derivative obligation 2,000 Balance – September 30, 2019 $ 3,000

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Cost of revenues $ 1,000 $ 3,000 $ 2,000 $ 9,000 Sales and marketing 110,000 11,000 166,000 29,000 Research and development 38,000 30,000 75,000 86,000 General and administrative 104,000 131,000 216,000 351,000 $ 253,000 $ 175,000 $ 459,000 $ 475,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2018 302,368 $ 13.99 Granted 10,200 $ 4.38 Forfeited (16,539 ) $ 11.50 Outstanding at September 30, 2019 296,029 $ 13.80 8.6 $ 763,499 Vested and expected to vest at September 30, 2019 215,932 $ 15.95 8.4 $ 525,700 Exercisable at September 30, 2019 94,978 $ 25.70 7.6 $ 171,726
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2018 1,726,523 $ 29.88 Warrants granted (1) 444,445 $ 0.10 Warrants expired (19,637 ) $ 417.00 Warrants exercised (416,500 ) $ 0.10 Outstanding at September 30, 2019 1,734,831 $ 25.02 Exercisable at September 30, 2019 1,664,978 $ 22.72

Note 9 - Segment Reporting (Tab

Note 9 - Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Three Months Ended September 30, 2019 Device Clinical Development Total Net revenues $ 4,045,000 $ 13,000 $ 4,058,000 Cost of revenues 2,126,000 37,000 2,163,000 Gross profit 1,919,000 (24,000 ) 1,895,000 Operating expenses 1,871,000 354,000 2,225,000 Operating income / (loss) $ 48,000 $ (378,000 ) $ (330,000 ) Depreciation and amortization $ 149,000 $ 53,000 $ 202,000 Stock-based compensation expense $ 201,000 $ 52,000 $ 253,000 Three Months Ended September 30, 2018 Device Clinical Development Total Net revenues $ 3,059,000 $ 54,000 $ 3,113,000 Cost of revenues 2,383,000 75,000 2,458,000 Gross profit 676,000 (21,000 ) 655,000 Operating expenses 1,969,000 621,000 2,590,000 Operating loss $ (1,293,000 ) $ (642,000 ) $ (1,935,000 ) Depreciation and amortization $ 100,000 $ 74,000 $ 174,000 Stock-based compensation expense $ 8,000 $ 167,000 $ 175,000 Nine Months Ended September 30, 2019 Device Clinical Development Total Net revenues $ 11,256,000 $ 69,000 $ 11,325,000 Cost of revenues 6,082,000 138,000 6,220,000 Gross profit 5,174,000 (69,000 ) 5,105,000 Operating expenses 5,295,000 1,307,000 6,602,000 Operating loss $ (121,000 ) $ (1,376,000 ) $ (1,497,000 ) Depreciation and amortization $ 381,000 $ 223,000 $ 604,000 Stock-based compensation expense $ 294,000 $ 165,000 $ 459,000 Goodwill $ 781,000 $ -- $ 781,000 Total assets $ 15,620,000 $ 1,971,000 $ 17,591,000 Nine Months Ended September 30, 2018 Device Clinical Development Total Net revenues $ 6,822,000 $ 162,000 $ 6,984,000 Cost of revenues 5,419,000 195,000 5,614,000 Gross profit 1,403,000 (33,000 ) 1,370,000 Operating expenses 6,858,000 30,208,000 37,066,000 Operating loss $ (5,455,000 ) $ (30,241,000 ) $ (35,696,000 ) Depreciation and amortization $ 296,000 $ 210,000 $ 506,000 Impairment Charges $ -- $ 27,202,000 $ 27,202,000 Stock-based compensation expense $ 88,000 $ 387,000 $ 475,000 Total assets $ 10,213,000 $ 11,386,000 $ 21,599,000

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	Jun. 04, 2019	Mar. 31, 2019USD ($)	Sep. 30, 2019USD ($)shares	Jan. 01, 2019	Dec. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ 687,000		$ (1,711,000)
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized | shares			350,000,000		350,000,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance			$ 2,800,000		$ 2,400,000
Working Capital			5,435,000		$ 2,261,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit, Total			8,713,000
Line of Credit Facility, Maximum Borrowing Capacity			10,000,000			$ 10,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest		$ 2,843,000	2,843,000
ThermoGenesis [Member]
Ownership in Subsidiary Exchanged				20.00%
Noncontrolling Interest, Ownership Percentage by Parent				100.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			(1,711,000)
CAR-TXpress [Member]
Minority Interest Acquired Through Exchange				20.00%
Noncontrolling Interest, Ownership Percentage by Parent				80.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ 1,100,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Aug. 30, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)shares	Sep. 30, 2018shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Right-of-Use Asset		$ 887,000	$ 887,000
Contract with Customer, Liability, Revenue Recognized		50,000	480,000
Contract with Customer, Liability, Current		840,000	$ 840,000			$ 485,000
Number of Reportable Segments			2
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			7,720,082	6,175,520
Operating Lease, Liability, Total		$ 904,000	$ 904,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			324,444
Supply Agreement [Member]
Supply Agreement, Term	5 years
Supply Agreement, Renewal Term	2 years
Contract with Customer, Liability, Total	$ 2,000,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset					$ 966,000
Operating Lease, Liability, Total					$ 966,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Net revenues	$ 4,058,000	$ 3,113,000	$ 11,325,000	$ 6,984,000
Device [Member]
Net revenues	4,045,000	3,059,000	11,256,000	6,822,000
Device [Member] | AXP [Member]
Net revenues	2,306,000	1,466,000	6,710,000	3,131,000
Device [Member] | BioArchive [Member]
Net revenues	594,000	799,000	2,391,000	2,326,000
Device [Member] | Manual Disposables [Member]
Net revenues	212,000	254,000	711,000	716,000
Device [Member] | CAR-TXpress [Member]
Net revenues	914,000	517,000	1,404,000	547,000
Device [Member] | Other Subsegments [Member]
Net revenues	19,000	23,000	40,000	102,000
Clinical Development [Member]
Net revenues	13,000	54,000	69,000	162,000
Clinical Development [Member] | Manual Disposables [Member]
Net revenues	9,000	8,000	53,000	31,000
Clinical Development [Member] | Other Subsegments [Member]
Net revenues	4,000	6,000	16,000	30,000
Clinical Development [Member] | Bone Marrow [Member]
Net revenues		40,000		101,000
Device Revenue [Member]
Net revenues	3,594,000	2,660,000	9,958,000	5,627,000
Device Revenue [Member] | Device [Member]
Net revenues	3,585,000	2,652,000	9,900,000	5,596,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	2,255,000	1,396,000	6,550,000	2,930,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	243,000	485,000	1,274,000	1,357,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	212,000	254,000	711,000	716,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	875,000	517,000	1,365,000	547,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues				46,000
Device Revenue [Member] | Clinical Development [Member]
Net revenues	9,000	8,000	58,000	31,000
Device Revenue [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues	9,000	8,000	53,000	31,000
Device Revenue [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues			5,000
Device Revenue [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues
Service [Member]
Net revenues	412,000	430,000	1,294,000	1,301,000
Service [Member] | Device [Member]
Net revenues	408,000	384,000	1,283,000	1,170,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	51,000	70,000	160,000	201,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	351,000	314,000	1,117,000	969,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	6,000		6,000
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Service [Member] | Clinical Development [Member]
Net revenues	4,000	46,000	11,000	131,000
Service [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues	4,000	6,000	11,000	30,000
Service [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues		40,000		101,000
Other [Member]
Net revenues	52,000	23,000	73,000	56,000
Other [Member] | Device [Member]
Net revenues	52,000	23,000	73,000	56,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	33,000		33,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	19,000	23,000	40,000	56,000
Other [Member] | Clinical Development [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Other Subsegments [Member]
Net revenues
Other [Member] | Clinical Development [Member] | Bone Marrow [Member]
Net revenues

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018
Anti-dilutive securities (in shares)		7,720,082	6,175,520
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		6,013,667	4,626,667
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		40,442	40,442
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	69,853	69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		1,300,091	1,319,728
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		296,029	118,830
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($)	Mar. 12, 2018	Aug. 21, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 31, 2019	Apr. 16, 2018	Apr. 01, 2018	Mar. 31, 2017
Amortization of Debt Discount (Premium)					$ 1,799,000	$ 800,000
Interest Expense, Total			$ 1,188,000	$ 835,000	3,531,000	1,928,000
Adjustments for New Accounting Principle, Early Adoption [Member] | Accounting Standards Update 2017-11 [Member]
Debt Instrument, Unamortized Discount, Total								$ 1,513,000		$ 7,200,000
Amortization of Debt Discount (Premium)			586,000	450,000	1,758,000	800,000
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price							$ 1.80		$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			10,000,000		10,000,000						$ 10,000,000
Proceeds from Long-term Lines of Credit					8,713,000		$ 7,200,000
Line of Credit Facility, Remaining Borrowing Capacity			$ 1,287,000		$ 1,287,000
Debt Instrument, Interest Rate, Stated Percentage			22.00%		22.00%
Interest Expense, Total			$ 471,000	385,000	$ 1,398,000	1,128,000
Interest Payable			1,398,000		1,398,000		$ 1,513,000
Boyalife W.S.N. [Member]
Distributor Agreement Term		3 years
Distributor Agreement, Renewal Term		2 years
Revenue from Related Parties			214,000	267,000	794,000	536,000
IncoCell [Member]
Contract Development Revenue, Term	10 years
IncoCell [Member] | Product [Member]
Revenue from Related Parties			82,000	7,000	82,000	7,000
IncoCell [Member] | Contract Development [Member]
Revenue from Related Parties			$ 0	$ 0	$ 0	$ 0

Note 4 - Convertible Promisso_3

Note 4 - Convertible Promissory Note (Details Textual) - USD ($)	Jul. 23, 2019	Jan. 29, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	May 30, 2019
Amortization of Debt Discount (Premium)					$ 1,799,000	$ 800,000
Gain (Loss) on Extinguishment of Debt, Total			$ (840,000)		(840,000)
Interest Expense, Total			1,188,000	$ 835,000	3,531,000	$ 1,928,000
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90.00%
Debt Instrument, Interest Rate, Stated Percentage		24.00%
Debt Instrument, Term		1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers		4.99%
Debt Instrument, Convertible, Second customary conversion blockers		9.99%
Debt Instrument, Unamortized Discount, Total							$ 800,000
Amortization of Debt Discount (Premium)			60,000		117,000
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount		$ 800,000
Debt Instrument, Convertible, Conversion Price		$ 1.80
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price		$ 0.50
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Unamortized Discount, Total			556,000		556,000
Amortization of Debt Discount (Premium)			20,000		57,000
Gain (Loss) on Extinguishment of Debt, Total			840,000
Long-term Debt, Fair Value			1,473,000		$ 1,473,000
Debt Conversion, Original Debt, Amount			$ 216,000
Debt Conversion, Converted Instrument, Shares Issued			120,000
Interest Expense, Total			$ 30,000
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.80
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.50
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.50

Note 4 - Convertible Promisso_4

Note 4 - Convertible Promissory Note - Assumptions (Details) - Convertible Debt [Member]	Jul. 23, 2019
Measurement Input, Share Price [Member]
Long-term Debt, Measurement Input	3.05
Measurement Input, Exercise Price [Member]
Long-term Debt, Measurement Input	1.8	[1]
Measurement Input, Risk Free Interest Rate [Member]
Long-term Debt, Measurement Input	1.8
Measurement Input, Expected Dividend Rate [Member]
Long-term Debt, Measurement Input
Measurement Input, Expected Term [Member]
Long-term Debt, Measurement Input	3.02
Measurement Input, Price Volatility [Member]
Long-term Debt, Measurement Input	93
[1]	For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 share or 90% of the listed price of the stock on the day of conversion, whichever is lower (subject to a floor of $0.50).

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Operating Lease, Weighted Average Remaining Lease Term		4 years 255 days	4 years 255 days
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 966,000		$ 966,000
Operating Lease, Payments		$ 74,000	217,000
Operating Lease, Cost		$ 103,000	$ 309,000

Note 5 - Leases - Lease Informa

Note 5 - Leases - Lease Information (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Right-of-use operating lease assets, net	$ 887,000
Current lease liability	110,000
Non-current lease liability	$ 794,000
Weighted average remaining lease term (Year)	4 years 255 days
Discount rate	22.00%

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details)	Sep. 30, 2019USD ($)
Period of October 1, 2019 through December 31, 2019	$ 74,000
2020	301,000
2021	310,000
2022	319,000
2023	329,000
2024	138,000
Total lease payments	1,471,000
Less: imputed interest	(567,000)
Present value of operating lease liabilities	$ 904,000

Note 6 - Commitments and Cont_3

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Oct. 31, 2017	Jun. 30, 2019	Sep. 30, 2019	Jun. 30, 2018
Payment Terms, Severance Compensation				1 year
Short Term Investment Minimum				$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency, Damages Sought, Value, Interest			$ 300,000
Loss Contingency, Negotiation Condition Bond		$ 1,000,000
Loss Contingency Accrual, Ending Balance				$ 0	$ 0

Note 6 - Commitments and Cont_4

Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	9 Months Ended
	Sep. 30, 2019USD ($)
Balance	$ 186,000
Warranties issued during the period	242,000
Settlements made during the period	(141,000)
Changes in liability for pre-existing warranties during the period	(39,000)
Balance	$ 248,000

Note 7 - Derivative Obligatio_3

Note 7 - Derivative Obligations (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jun. 30, 2016
Class of Warrant or Right, Outstanding	1,734,831		1,734,831		1,726,523
Derivative, Gain (Loss) on Derivative, Net, Total	$ (2,000)	$ 24,000	$ (2,000)	$ 591,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding						40,442

Note 7 - Derivative Obligatio_4

Note 7 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member]	Sep. 30, 2019	Dec. 31, 2018
Measurement Input, Share Price [Member]
Valuation assumption	6.63	2.7
Measurement Input, Price Volatility [Member]
Valuation assumption	0.93	0.94
Measurement Input, Expected Term [Member]
Valuation assumption	1.4	2.2
Measurement Input, Discount Rate [Member]
Valuation assumption	0.017	0.0248
Measurement Input, Expected Dividend Rate [Member]
Valuation assumption	0	0
Measurement Input, Exercise Price [Member]
Valuation assumption	80	80

Note 7 - Derivative Obligatio_5

Note 7 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Derivative obligations	$ 3,000	$ 1,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 3,000	$ 1,000

Note 7 - Derivative Obligatio_6

Note 7 - Derivative Obligations - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Balance			$ 1,000
Change in fair value of derivative obligation	$ 2,000	$ (24,000)	2,000	$ (591,000)
Balance	$ 3,000		$ 3,000

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - USD ($)		Apr. 18, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Class of Warrant or Right, Issued During Period	[1]				444,445
Share-based Payment Arrangement, Expense			$ 253,000	$ 175,000	$ 459,000	$ 475,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					0
April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Issued During Period		444,445
Warrants Issued, Price Per Warrant		$ 1.70
Proceeds from Issuance of Warrants		$ 756,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.10
[1]	See Footnote 1 of the Notes to the Condensed Consolidated Financial Statements.

Note 8 - Stockholder's Equity -

Note 8 - Stockholder's Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Expense	$ 253,000	$ 175,000	$ 459,000	$ 475,000
Cost of Sales [Member]
Share-based Payment Arrangement, Expense	1,000	3,000	2,000	9,000
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expense	110,000	11,000	166,000	29,000
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	38,000	30,000	75,000	86,000
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense	$ 104,000	$ 131,000	$ 216,000	$ 351,000

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	302,368
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 13.99
Granted, options (in shares) | shares	10,200
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 4.38
Forfeited, options (in shares) | shares	(16,539)
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares	$ 11.50
Outstanding, options (in shares) | shares	296,029
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 13.80
Outstanding, weighted average remaining contractual life, options (Year)	8 years 219 days
Outstanding, aggregate intrinsic value, options | $	$ 763,499
Vested and Expected to Vest, options (in shares) | shares	215,932
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 15.95
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	8 years 146 days
Vested and Expected to Vest, aggregate intrinsic value, options | $	$ 525,700
Exercisable, options (in shares) | shares	94,978
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 25.70
Exercisable, weighted average remaining contractual life, options (Year)	7 years 219 days
Exercisable, aggregate intrinsic value, options | $	$ 171,726

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Outstanding (in shares) | shares	1,726,523
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 29.88
Warrants granted(1) (in shares) | shares	444,445	[1]
Warrants granted(1) (in dollars per share) | $ / shares	$ 0.10	[1]
Warrants expired (in shares) | shares	(19,637)
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares	$ 417
Warrants exercised (in shares) | shares	(416,500)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.10
Outstanding (in shares) | shares	1,734,831
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 25.02
Exercisable (in shares) | shares	1,664,978
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 22.72
[1]	See Footnote 1 of the Notes to the Condensed Consolidated Financial Statements.

Note 9 - Segment Reporting (Det

Note 9 - Segment Reporting (Details Textual)	9 Months Ended
	Sep. 30, 2019
Number of Reportable Segments	2

Note 9 - Segment Reporting - Su

Note 9 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Net revenues	$ 4,058,000	$ 3,113,000	$ 11,325,000	$ 6,984,000
Cost of revenues	2,163,000	2,458,000	6,220,000	5,614,000
Gross profit	1,895,000	655,000	5,105,000	1,370,000
Operating expenses	2,225,000	2,590,000	6,602,000	37,066,000
Operating income (loss)	(330,000)	(1,935,000)	(1,497,000)	(35,696,000)
Depreciation and amortization	202,000	174,000	604,000	506,000
Stock-based compensation expense	253,000	175,000	459,000	475,000
Goodwill	781,000		781,000		$ 781,000
Total assets	17,591,000	21,599,000	17,591,000	21,599,000	$ 14,611,000
Impairment Charges				27,202,000
Clinical Development [Member]
Net revenues	13,000	54,000	69,000	162,000
Clinical Development [Member] | Operating Segments [Member]
Net revenues	4,045,000	3,059,000	11,256,000	6,822,000
Cost of revenues	2,126,000	2,383,000	6,082,000	5,419,000
Gross profit	1,919,000	676,000	5,174,000	1,403,000
Operating expenses	1,871,000	1,969,000	5,295,000	6,858,000
Operating income (loss)	48,000	(1,293,000)	(121,000)	(5,455,000)
Depreciation and amortization	149,000	100,000	381,000	296,000
Stock-based compensation expense	201,000	8,000	294,000	88,000
Goodwill	781,000		781,000
Total assets	15,620,000	10,213,000	15,620,000	10,213,000
Impairment Charges
Device [Member]
Net revenues	4,045,000	3,059,000	11,256,000	6,822,000
Device [Member] | Operating Segments [Member]
Net revenues	13,000	54,000	69,000	162,000
Cost of revenues	37,000	75,000	138,000	195,000
Gross profit	(24,000)	(21,000)	(69,000)	(33,000)
Operating expenses	354,000	621,000	1,307,000	30,208,000
Operating income (loss)	(378,000)	(642,000)	(1,376,000)	(30,241,000)
Depreciation and amortization	53,000	74,000	223,000	210,000
Stock-based compensation expense	52,000	167,000	165,000	387,000
Goodwill
Total assets	$ 1,971,000	$ 11,386,000	$ 1,971,000	11,386,000
Impairment Charges				$ 27,202,000

Note 10 - Major Customers and_2

Note 10 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Revenue Benchmark [Member] | Customer 1 [Member]
Concentration Risk, Percentage	27.00%	15.00%	29.00%	19.00%
Revenue Benchmark [Member] | Customer 2 [Member]
Concentration Risk, Percentage	13.00%	15.00%	13.00%	7.00%
Accounts Receivable [Member]
Number of Major Customers			3		4
Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage			72.00%
Accounts Receivable [Member] | Four Customers [Member]
Concentration Risk, Percentage					77.00%

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - Subsequent Event [Member] - ImmuneCyte [Member] $ in Millions	Nov. 01, 2019USD ($)
Equity Method Investment, Ownership Percentage	20.00%
Joint Venture Purchase, Percent of Company's Cost	115.00%
Line of Credit Facility, Maximum Borrowing Capacity	$ 1